Company Overview and News

0
WOW Unlimited Media Inc. Announces Completion of Non-Brokered Private Placement

2018-06-12 globenewswire
TORONTO, Ontario and VANCOUVER, B.C., June 11, 2018 (GLOBE NEWSWIRE) -- WOW Unlimited Media Inc. (TSXV:WOW.A) (TSXV:WOW.B) (the “Company” or “WOW”) is pleased to announce that it has completed a non-brokered private placement offering (the “Offering”) of an aggregate of 1,573,527 common voting shares and variable voting shares at a price of $1.50 per share for aggregate gross proceeds of $2.36 million.
RNK RNKFF RNK.DB

0
Wow Unlimited Media Announces Financial Results for the First Quarter of 2018

2018-05-31 globenewswire
VANCOUVER, British Columbia, May 30, 2018 (GLOBE NEWSWIRE) -- Wow Unlimited Media Inc. (“Wow” or the “Company”) (TSX-V:WOW.A) (TSX-V:WOW.B) announced its results for the three months ended March 31, 2018.
RNK RNKFF RNK.DB

0
Wow Unlimited Media Announces Financial Results for Fiscal Year End 2017

2018-04-27 globenewswire
VANCOUVER, British Columbia, April 27, 2018 (GLOBE NEWSWIRE) -- Wow Unlimited Media Inc. (“Wow” or the “Company”) (TSX-V:WOW.A) (TSX-V:WOW.B) announced its fourth quarter and fiscal year-end results for the period ended December 31, 2017. The Company reported the following highlights from the year ended December 31st, 2017:
RNK CJREF CJR.B RNKFF RNK.DB

0
WOW! Unlimited Media Inc. to Present at the Planet MicroCap Showcase 2018 on April 25 in Las Vegas, NV

2018-04-11 accesswire
TORONTO, ON / ACCESSWIRE / April 11, 2018 / WOW! Unlimited Media Inc.'s (TSXV: WOW.A) (TSXV: WOW.B), leading next-generation kids and youth entertainment company, will present at the Planet MicroCap Showcase at 10:30 am (PST) on Wednesday, April 25, 2018, and will conduct 1on1 meetings on April 26, 2018.
RNK RNKFF RNK.DB

0
WOW! Unlimited Media’s Frederator Networks Grows Its Roster of Animation Content for All Audiences

2018-04-10 globenewswire
NEW YORK AND VANCOUVER, British Columbia AND TORONTO, April 10, 2018 (GLOBE NEWSWIRE) -- WOW! Unlimited Media Inc.’s (TSXV:WOW.A) (TSXV:WOW.B) (the "Company" or "WOW") company Frederator Networks is at the forefront of next-generation kids and youth animation as a vertically-integrated company that consists of Frederator Studios and Frederator Digital.
RNK CJREF CJR.B RNKFF RNK.DB

0
WOW Unlimited Media’s Mainframe Studios Debuts New Productions

2018-03-28 globenewswire
TORONTO, March 28, 2018 (GLOBE NEWSWIRE) -- WOW Unlimited Media Inc. continues to make inroads in the competitive marketplace of kids and youth entertainment. Mainframe Studios, WOW’s Vancouver based animated and live-action television production studio, is about to debut projects that reach a broad demographic. While it continues to offer traditionally accessible fare, the company is embracing the new digital options that showcase its innovation and production expertise.
RNK RNKFF RNK.DB

0
WOW! Provides Revenue Estimates

2018-03-26 globenewswire
VANCOUVER, British Columbia, March 26, 2018 (GLOBE NEWSWIRE) -- WOW Unlimited Media Inc. (TSXV:WOW.A) (TSXV:WOW.B) (the "Company" or "WOW") is pleased to announce that it expects revenue for its fourth quarter of 2017 to be approximately $15 million to $17 million (revenue in the third quarter of 2017 was $10 million), which would result in fiscal 2017 revenue of approximately $42 million to $44 million.
RNK RNKFF RNK.DB

Related Articles

ARWR: Arrowhead Pharmaceuticals Analysis and Research Report

9h - Asif

Business Arrowhead develops medicines that treat intractable diseases by silencing the genes that cause them. Using a broad portfolio of RNA chemistries and efficient modes of delivery, Arrowhead therapies trigger the RNA interference mechanism to induce rapid, deep and durable knockdown of target genes. RNA interference, or RNAi, is a mechanism present in living cells that inhibits the expression of a specific gene, thereby affecting the production of a specific protein. Deemed to be one of the most important recent discoveries in life science with the potential to transform medicine, the discoverers of RNAi were awarded a Nobel Prize in 2006 for their work. Arrowhead’s RNAi-based therapeutics leverage this natural pathway of gene silencing. In fiscal 2017, Arrowhead refocused its resources on therapeutics that exclusively utilize the company’s Targeted RNAi Molecule (TRiMTM) platform technology. Therapeutics built on the TRiMTM platform have demonstrated high levels of pha...

PRTO: Proteon Therapeutics Analysis and Research Report

2018-06-11 - Asif

Overview Proteon Therapeutics is a late-stage biopharmaceutical company focused on the development of novel, first-in-class pharmaceuticals to address the needs of patients with renal and vascular disease. The company's product candidate, vonapanitase, is a recombinant human elastase that Proteon Therapeutics is developing to improve vascular access outcomes in patients with chronic kidney disease, or CKD, undergoing or planning for hemodialysis, a lifesaving treatment that cannot be conducted without a functioning vascular access. The company believe data from its completed Phase 2 and Phase 3 clinical trials of vonapanitase support that a one-time, local application of investigational vonapanitase during surgical creation of a radiocephalic fistula for hemodialysis may improve fistula use for hemodialysis and secondary patency (time to fistula abandonment), thereby improving patient outcomes and reducing the burden on patients and the healthcare system. Arteriovenous fistu...

GALE: Galena Biopharma Analysis and Research Report

2018-06-11 - Asif

Overview Galena Biopharma is a clinical-stage biopharmaceutical company focused on novel cancer immunotherapeutics for a broad range of cancer indications. The company's lead product candidate, galinpepimut-S, or GPS, is a cancer i unotherapeutic agent licensed from Memorial Sloan Kettering Cancer Center, or MSK, that targets the Wilms tumor 1, or WT1, protein, which is present in 20 or more cancer types. Based on its mechanism of action as a directly immunizing agent, GPS has the potential as a monotherapy or in combination with other immunotherapeutic agents to address a broad spectrum of hematologic, or blood, cancers and solid tumor indications. Phase 2 clinical trials for GPS have been completed and Galena Biopharma has planned Phase 3 clinical trials (pending funding availability) for two indications, acute myeloid leukemia, or AML, and malignant pleural mesothelioma, or MPM. GPS is also in development as a potential treatment for multiple myeloma, or MM, and ovarian can...